Amgen to reveal oncology data at ASCO meeting

Amgen intends to present clinical data for nine different products at the annual meeting of the American Society of Clinical Oncology (ASCO) next month.

The pharmaceutical firm announced that data concerning the XGEVA (denosumab), Vectibix (panitumumab), ganitumab (AMG 479) and AMG 386 programmes will be among the information shared at the US event.

Sean Harper, senior vice-president, global development and corporate chief medical officer at Amgen, said the data will "provide important insights into the benefit-risk profiles of several of our pipeline molecules".

He added that the company's researchers are "passionate about developing new and innovative therapies for patients with cancer".

Data from a phase III study comparing denosumab with placebo as an adjuvant treatment for women with early-stage breast cancer will be one of several XGEVA abstracts presented by Amgen.

The ASCO meeting is due to run from Friday June 3rd to Tuesday June 7th at McCormick Place in Chicago.